Amphastar Pharmaceuticals Inc Shares Climb 0.7% Past Previous 52-Week High - Market Mover
The shares rose 0.7% higher than its previous 52-week high of $25.87, with trading volume lower than its 30 day average
Jan 29, 2022 by Kwhen Finance Editors
Amphastar Pharmaceuticals Inc (AMPH) shares closed 0.7% higher than its previous 52 week high, giving the company a market cap of $1B. The stock is currently up 7.5% year-to-date, up 32.9% over the past 12 months, and up 60.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.6%, and the S&P 500 fell 3.5%.
Trading Activity
- Trading volume this week was 43.5% lower than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
- The stock closed at 3.9% higher than its 5-day moving average, 5.8% higher than its 20-day moving average, and 22.8% higher than its 90-day moving average.
Fundamentals & Catalysts
- Over the past 12 months the company generated $39 million in earnings before interest and taxes from $368 million in revenue. It currently holds $115 million in cash and $127 million in debt.
- Its forward price-to-earnings (P/E) ratio of 19.001434317247796 is lower than its current P/E ratio of 33.19, implying that analysts are expecting an increase in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -3.79. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 1.59 which means it currently has $1.59 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 2.22. This means that the stock is trading at a premium of 2 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 2.45.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 2.26.
P/E
33.19
EBITDA
$39M
P/Book
2.22
Mkt Cap
$1B
P/Sales
2.45
Revenue
$368M
EPS (TTM)
0.72
PEG Ratio
-3.79
EV/Revenue
2.26
Total Cash
$115M
Debt/Equity
1.59
Forward P/E
19.00
Current Debt
$127M
Gross Profit
$151M
Dividend Date
-
Earnings Date
2022-03-15
Profit Margin
0.01
Revenue/Share
7.73
Total Revenue
$368M
Enterprise Val
$830M
Put/Call Ratio
6.53
Revenue/Employee
184089.00
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 4.1 | 7.5 | 32.9 | -3.4 | 47.7 |
| Dow Jones Industrial Average | 1.6 | -5.9 | 14.6 | -7.4 | 16.5 |
| S&P 500 Index | 2.5 | -9.2 | 16.7 | -9.9 | 19.1 |
| Health Care | 2.2 | -10.8 | 8.6 | -11.5 | 13.7 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date beats the peer average by -123.7%
- The company's stock price performance over the past 12 months beats the peer average by -157.8%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | AMPH | 33.2 | 7.5 | 32.9 | -3.4 | 47.7 |
| Peer Avg | N/A | 0 | -31.5 | -56.9 | -72.7 | 6.1 |
| Marinus Pharmaceuticals Inc | MRNS | 0 | -20.6 | -26.0 | -52.7 | 4.2 |
| Tonix Pharmaceuticals Holding Corp | TNXP | 0 | -39.2 | -77.1 | -89.6 | 9.8 |
| Scynexis Inc | SCYX | 0 | -26.2 | -35.1 | -56.1 | 6.9 |
| Agile Therapeutics Inc | AGRX | 0 | -39.8 | -89.6 | -92.3 | 3.6 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: